Skip to content
Compare stocks

City Therapeutics vs Vor Biopharma stock comparison

Score, categories, valuation, dividend, crash risk and price performance of City Therapeutics and Vor Biopharma side by side. Figures from the overnight run, closing prices from 19 Nov 2026.

Key figures compared

CTYCity TherapeuticsVORVor Biopharma
MEQIRI Score
Score5845
Fundamentals9120
Growth3350
Profitability8214
Valuationno datano data
Technical analysis3961
Momentum1982
Stability6249
Capital allocation6462
Price and valuation
Closing price$18.35$18.52
Market cap$979.67M$1B
P/Eno dataLoss
Forward P/Eno datano data
Fair valueno datano data
Fair value versus priceno datano data
Growth and dividend
Revenue growth per year−1.6%no data
Dividend yield0.0%0.0%
Risk and performance
Crash riskno datano data
Price 1 yearno data+136.8%
Price 5 yearsno data−93.2%
IndustryBiotechnologyBiotechnology

Score and figures from the overnight run, closing prices from 19 Nov 2026. Amounts in US dollars, converted at the ECB rate. Price performance without dividends. The comparison shows figures and is not a recommendation to buy.

Price performance

  • City Therapeutics
  • Vor Biopharma

All lines start at 100 on 15 October 2026. Closing prices without dividends, each stock in its trading currency.

Questions and Answers

How do City Therapeutics and Vor Biopharma compare on the MEQIRI Score?

The MEQIRI Score (0 to 100) is 58 for City Therapeutics and 45 for Vor Biopharma. The category Fundamentals differs most, with 91 for City Therapeutics and 20 for Vor Biopharma. The score combines eight categories and is recalculated every night.

What is the P/E ratio of City Therapeutics and Vor Biopharma?

City Therapeutics: P/E no data, forward P/E no data. Vor Biopharma: P/E Loss, forward P/E no data. As of the close on 19 Nov 2026.

What is the dividend yield of City Therapeutics and Vor Biopharma?

City Therapeutics: 0.0%. Vor Biopharma: 0.0%. Based on payments over the last twelve months.

What is the crash risk of City Therapeutics and Vor Biopharma?

City Therapeutics: no data. Vor Biopharma: no data. Crash risk means a fall of 30% or more within a year, measured in the backtest against companies of similar size.

Why does the price chart start at 100?

All lines start at 100 on the same day. That shows performance regardless of a stock's price: 150 means 50% more than at the start, 80 means 20% less.

Does the comparison tell me which stock to buy?

No. MEQIRI shows figures and explains them, but gives no buy recommendation and no price target. The score helps you see strengths and weaknesses faster.

More comparisons

Compare stocks